+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparative Study of Different Treatment Options of Grade III and IV Diabetic Foot Ulcers to Reduce the Incidence of Amputations



Comparative Study of Different Treatment Options of Grade III and IV Diabetic Foot Ulcers to Reduce the Incidence of Amputations



Clinics and Practice 3(1): E9



THIS STUDY AIMS TO COMPARE THE EFFICACY OF ANTISEPTIC DRESSINGS, HYPERBARIC OXYGEN THERAPY, AND RECOMBINANT HUMAN PLATELET DERIVED GROWTH FACTOR (RHPDGF) FOR TWO REASONS: i) to reduce the incidence of lower limb amputations in diabetic foot ulcer; ii) to limit the duration of stay in the hospital. A prospective randomized trial was conducted on 60 patients with stage III and IV diabetic foot ulcers (International Association of Enterostomal Therapy classification) and patients were divided randomly in three different therapy groups - antiseptics, hyperbaric oxygen therapy, recombinant platelet derived growth factor, with 20 patients in each group. Patients were managed initially on inpatient and then on outpatient basis till the ulcer healed completely. Results among three groups were compared using unpaired T test and the level of significance was set at P<0.05 using ANOVA. This study compares the efficacy of hyperbaric oxygen therapy, antiseptic dressings, and rhPDGF in grade III and IV diabetic foot ulcers. P value (0.0348) was significant for complete wound contraction while p value healing time (0.6534) and ulcer size (0.0593) in the groups was not significant. PDGF is safe, effective and easy to apply. Results are comparable with hyperbaric oxygen (HBO) therapy and cost of treatment is lower than other therapies. Diabetic foot ulcer management requires multidisciplinary and aggressive approach. PDGF should be recommended for all grade III and IV diabetic foot ulcer at least 8 weeks old. HBO is equally good an option but has limitations and side effects.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052207932

Download citation: RISBibTeXText

PMID: 24765502

DOI: 10.4081/cp.2013.e9


Related references

Correct treatment of common diabetic foot infections can reduce amputations. 2012

Graftskin in the treatment of diabetic foot ulcers resulted in significantly lower rates of amputations. Wound Repair & Regeneration 9(2): 147, March-April, 2001

Disease management for the diabetic foot: effectiveness of a diabetic foot prevention program to reduce amputations and hospitalizations. Diabetes Research and Clinical Practice 70(1): 31-37, 2005

Vascular surgery, microsurgery and supramicrosurgery for treatment of chronic diabetic foot ulcers to prevent amputations. Plos One 8(9): E74704, 2014

The Reduction of Diabetic Foot Amputations Starts with Preventing Foot Ulcers. Advances in Skin and Wound Care 31(9): 389, 2018

Diabetic foot ulcers: current treatment options and new developments. Surgical Technology International 20: 97-105, 2012

Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatologic Surgery 27(4): 347-351, 2001

Foot ulcers in patients with diabetes. Preventive measures reduce the number of amputations. Lakartidningen 90(47): 4221-4224, 1993

Topical Phenytoin Application in Grade I and II Diabetic Foot Ulcers: A Prospective Study. Journal of Clinical and Diagnostic Research 7(10): 2238-2240, 2013

A comparative study between total contact cast and pressure-relieving ankle foot orthosis in diabetic neuropathic foot ulcers. Journal of Diabetes Science and Technology 9(2): 302-308, 2015

The cost of diabetic foot ulcers and amputations to the National Health Service in England. Diabetic Medicine 2019, 2019

The psychological assessment of diabetic people with or without foot ulcers or lower limb amputations. Hotta, N, Greene, D A, Ward, J D, Sima, A A F, Boulton, A J M International Congress Series; Diabetic neuropathy: New concepts and insights 159-165, 1995

Cellular versus acellular matrix devices in treatment of diabetic foot ulcers: study protocol for a comparative efficacy randomized controlled trial. Trials 14: 8, 2013

Geographic variation in Medicare spending and mortality for diabetic patients with foot ulcers and amputations. Journal of Diabetes and Its Complications 27(2): 128-133, 2013

Barriers to diabetic foot care in a developing country with a high incidence of diabetes related amputations: an exploratory qualitative interview study. Bmc Health Services Research 15: 377, 2016